Abstract:Background: A hybrid molecule of different biologically active substances can improve affinity and efficiency compared to a standard drug. Hence based on this fact, we predict that a combination of fluorine, oxadiazole, sulfur, etc., may enhance α-glucosidase inhibition activity compared to a standard drug. Methods: A series of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives (2a-2i) were synthesized and characterized using spectroscopic techniques such as 1HNMR and LC-MS. In order to evaluate its bioactivity, in vitro α-amylase and α-glycosidase inhibitory activity were performed. In vivo study was carried using a genetic model, Drosophila melanogaster, for assessing the antihyperglycemic effects. Results: The compounds 2a-2i demonstrated α-amylase inhibitory activity in the range of IC50 = 40.00-80.00 μg/ml as compare to standard acarbose (IC50 = 34.71 μg/ml). Compounds 2a-2i demonstrated α-glucosidase inhibitory activity in the range of IC50 = 46.01-81.65 μg/ml as compared to standard acarbose (IC50 = 34.72 μg/ml). Docking studies on a target protein, N-terminal subunit of human Maltase-glucoamylase (PDB:2QMJ) was carried and the compounds were found to dock into the active site of the enzyme (Fig. 1). The predicted binding energies of the compounds were calculated. The in vitro studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. Whereas in vivo study indicates that 2b, 2g, and 2i could lower glucose levels in the Drosophila, but then 17-30% reduced capacity than acarbose and may be overcome by adjusting their dosage. Conclusions: The in vitro and in vivo studies indicate that compounds 2b and 2g had better activity among the synthesized compounds. This study has recognized that compounds like 2b, 2g, and 2i may be considered potential candidates for further developing a novel class of antidiabetic agents.

Design, Synthesis, and Pharmacological Evaluation of 2-(1-(1,3,4-thiadiazol-2-yl)piperidin-4-yl)ethan-1-ol Analogs As Novel Glutaminase 1 Inhibitors.

Discovery of Novel Glutaminase 1 Allosteric Inhibitor with 4-Piperidinamine Linker and Aromatic Heterocycles.

Design, Synthesis, and Biological Evaluation of Novel Glutaminase 1 Allosteric Inhibitors with an Alkane Chain Tail Group.

Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs As Glutaminase Inhibitors

Design, Synthesis and Biological Evaluation of Potent Human Glyoxalase I Inhibitors.

Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site

Structural basis for 18-β-glycyrrhetinic acid as a novel non-GSH analog glyoxalase I inhibitor

Enhancing the Affinity of Novel GLS1 Allosteric Inhibitors by Targeting Key Residue Lys320.

Discovery and Optimization of Withangulatin A Derivatives As Novel Glutaminase 1 Inhibitors for the Treatment of Triple-Negative Breast Cancer.

Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors

Design, Synthesis, and Biological Evaluation of Thioglucoside Analogues of Gliflozin As Potent New Gliflozin Drugs.

Synthesis and Biological Evaluation of Novel N-Aryl-ω-(Benzoazol-2-yl)-Sulfanylalkanamides as Dual Inhibitors of α-Glucosidase and Protein Tyrosine Phosphatase 1B.

Design and structural optimization of thiadiazole derivatives with potent GLS1 inhibitory activity

Synthesis, Biological Evaluation, and Molecular Docking Studies of Novel Isatin-Thiazole Derivatives As Α-Glucosidase Inhibitors

Discovery of N‐(phenylsulfonyl)thiazole‐2‐carboxamides As Potent Α‐glucosidase Inhibitors

Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides As Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors

Design and Synthesis of Sulfonium Derivatives: A Novel Class of -Glucosidase Inhibitors with Potent In Vivo Antihyperglycemic Activities

Synthesis, Molecular Docking and Α-Glucosidase Inhibition of 2-((5,6-Diphenyl-1,2,4-triazin-3-yl)thio)-n-arylacetamides.

Synthesis, Crystal structure, Spectral analysis, DFT calculations, Docking studies, in vitro biological activity evaluation and in silico drug-likeness prediction of a novel L-xylose derivative

Development and Characterization of a Fluorescent Probe for GLS1 and the Application for High-Throughput Screening of Allosteric Inhibitors.

Novel oxadiazole analogues derived from ethacrynic acid: design, synthesis, and structure-activity relationships in inhibiting the activity of glutathione S-transferase P1-1 and cancer cell proliferation.